J. Joseph Kim
President and Chief Executive Officer
Joseph Kim is Chief Executive Officer of Inovio Pharmaceuticals, a drug development company bringing to medicine a novel class of synthetic vaccines for the treatment of influenza, HIV, cancer and other infectious diseases. Kim previously led efforts in the manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck & Co. He has published over 100 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. Kim is the recipient of numerous awards. MIT's Technology Review called him one of the world's “Top 100 Young Innovators” and Newsweek magazine profiled him as one of “10 leaders, scientists and executives at the forefront of change and impact in the world”. Kim studied economics, engineering and biological sciences at MIT where he was a US Senate Honors scholar. He holds a PhD in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.